文献速递艾滋病与性传播感染

核苷(酸)类逆转录酶抑制剂对病毒学抑制的HIV感染成人前瞻性队列中血液端粒长度变化的影响

Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults.
PubMed 文献 · J Infect Dis · 2018-01-01

前瞻性队列纳入172例病毒学抑制的HIV感染成人,比较当前暴露于富马酸替诺福韦二吡呋酯(TDF)与从未暴露者的全血端粒长度。随访2年,全队列平均端粒长度显著增加,但TDF组端粒长度增幅显著小于非TDF组;在非TDF组中,使用2种核苷类药物的参与者端粒长度增幅也显著小于使用不含N(t)RTI方案或仅拉米夫定者。

要点

  • 随访2年,全队列平均血液端粒长度显著增加。
  • TDF组端粒长度增幅显著小于非TDF组。
  • 非TDF组中,使用2种核苷类药物者端粒长度增幅显著小于不含N(t)RTI方案或仅拉米夫定者。

核心结论

  • 在长期病毒学抑制的HIV感染成人中,随访2年后,TDF或阿巴卡韦治疗与较小的血液端粒长度增幅相关。

研究设计与样本

  • 前瞻性队列研究,纳入病毒学抑制的HIV感染参与者,比较当前暴露于TDF者与从未暴露于TDF者的全血端粒长度(采用定量多重聚合酶链反应分析测量)。
  • 共纳入172例参与者:TDF组67例,非TDF组105例(其中75例使用2种核苷类药物,69例使用阿巴卡韦;25例使用不含核苷(酸)类逆转录酶抑制剂[N(t)RTI]的方案;5例仅使用拉米夫定作为唯一核苷类药物)。

主要发现

  • 随访2年后,全队列平均血液端粒长度显著增加。
  • TDF组端粒长度增幅显著小于非TDF组。
  • 在仅限接受N(t)RTI的参与者分析中,TDF暴露与独立负效应不相关。
  • 非TDF组中,使用2种核苷类药物的参与者端粒长度增幅显著小于使用不含N(t)RTI方案或仅拉米夫定者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. METHODS: A prospective cohort of human immunodeficiency virus (HIV)-infected participants with suppressed virological replication was recruited to compare whole-blood telomere length (measured by quantitative multiplex polymerase chain reaction analysis) in participants with current exposure to tenofovir disoproxil fumarate (TDF) to that in participants never exposed to TDF. RESULTS: A total of 172 participants were included: 67 were in the TDF group, and 105 were in the non-TDF group (75 were receiving 2 nucleosides [of whom 69 were receiving abacavir], 25 were receiving a nucleos[t]ide reverse transcriptase inhibitor [N{t}RTI]-sparing regimen, and 5 were receiving lamivudine as the only nucleoside). After 2 years, the mean blood telomere length increased significantly in the whole cohort. The TDF group had significantly smaller gains in telomere length than the non-TDF group. In the analysis restricted to participants receiving N(t)RTIs, TDF exposure was not associated with an independent negative effect. In the non-TDF group, participants treated with 2 nucleosides also had significantly smaller gains in telomere length than those receiving N(t)RTI-sparing regimens or lamivudine as the only nucleoside. DISCUSSION: In HIV-infected adults with prolonged virological suppression, treatment with TDF or abacavir was associated with smaller gains in blood telomere length after 2 years of follow-up.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Montejano R, Stella-Ascariz N, Monge S, et al. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. J Infect Dis. 2018. PMID: 29912427. doi:10.1093/infdis/jiy364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。